
UTMB develops a universal vaccine platform that’s cheaper and shelf stable
UTMB develops a universal vaccine platform that’s cheaper and shelf stable
Researchers at The University of Texas Medical Branch at Galveston have developed a less expensive way to produce vaccines that cuts the cost of vaccine production and storage by 80 percent without decreasing safety or effectiveness. The findings are currently available in EBioMedicine.
Vaccines are the most effective way to prevent and eradicate infectious diseases. Currently, many vaccines have to be manufactured in cell culture or eggs, which is expensive and carries the risk of contaminations. In addition, most vaccines must be kept refrigerated during the transportation from manufacturers to health care clinics. In tropical and subtropical regions, such cold storage requirements could contribute to more than 80 percent of the vaccine cost.
“The ability to eliminate cell culture or eggs and cold storage will change the process of vaccine development,” said UTMB’s Pei-Yong Shi, professor in the department of biochemistry and molecular biology. “Importantly, this vaccine technology could potentially serve as a universal platform for development of live-attenuated vaccines for many viral pathogens.”
To achieve these goals, the UTMB team engineered a live-attenuated Zika vaccine in the DNA form. Once the DNA is delivered into our body, it launches the vaccine in our cells, leading to antibody production and other protective immunity. With this production method, there is no need to manufacture the vaccine in cell culture or eggs at factories. Because DNA molecules are shelf stable, the vaccine will not expire at warm temperatures and could be stockpiled at room temperature for years.
Using UTMB’s Zika vaccine as a model, the research group showed that the DNA platform worked very efficiently in mice. After a single low dose, the DNA vaccine protected mice from Zika virus infection, mother-to-fetus transmission during pregnancy and male reproductive tract infection and damage.
“This is the first study to demonstrate that, after a single low dose, a DNA vaccine could induce saturated protective immunity,” Shi said. “We will continue testing this promising Zika vaccine platform and then apply the platform to other viruses.”
Learn more: UTMB develops a universal vaccine platform that’s cheaper and shelf stable
The Latest on: Vaccine production
[google_news title=”” keyword=”vaccine production” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Vaccine production
- The CDC and FDA downplay an alert over a COVID vaccine’s link to strokes in seniorson January 17, 2023 at 3:00 am
Plus, the shortage of children’s flu medication has ended, why a dozen eggs costs more than a gallon of gasoline, and more.
- Pallavi Joshi injured after out-of-control vehicle hits her on sets of Vivek Agnihotri's The Vaccine Waron January 17, 2023 at 2:14 am
Pallavi Joshi suffered an injury on the sets of The Vaccine War while shooting in Hyderabad for Vivek Agnihotri s next film The Vaccine War ...
- Podcaster Sam Harris: If COVID killed more children there'd be 'no f---ing patience' for vaccine skepticson January 17, 2023 at 2:12 am
There wouldn't have been the same kind of vaccine skepticism," he continued ... He also said Trump was worse than Usama Bin Laden. Joe Silverstein is a production assistant for Fox News Digital. Get ...
- Coming in From the Cold: Needle-free Patch Technology for Mrna Vaccines Aims to End Need for Frozen Storage and Improve Accesson January 17, 2023 at 1:12 am
Under the terms of the funding agreement, Vaxxas has committed to achieving equitable access to the outputs of this project including prioritization of supply for low-income and middle-income ...
- Rift Valley Fever Vaccines Market Size Identification of Industry Development [Potential Resource] Globally and Major Companies With Futureon January 16, 2023 at 8:05 pm
The Rift Valley Fever Vaccines market has witnessed growth from USD million to USD million from 2017 to 2022. With the CAGR, this market is estimated to reach USD million in 2029. The report focuses ...
- Oral Vaccine Adjuvants Market 2023 Report Offers Key Futuristic Top Trends And Competitive Landscape By 2029on January 16, 2023 at 7:30 pm
Pages Report] Rising demand for Medical Devices & Consumables Industry will drive the Oral Vaccine Adjuvants segment growth over the next five years. Global Market Analysis f ...
- Vaccine manufacturing in Africa – strategies to achieve the 2040 visionon January 16, 2023 at 4:26 pm
The Africa Centres for Disease Control and Prevention (Africa CDC) has set an ambitious target to manufacture 60% of Africa’s routine vaccine needs by ...
- Laurel apiary hopeful for future with new honey bee vaccineon January 16, 2023 at 2:48 pm
The US Department of Agriculture approved the first honey bee vaccine to target American foulbrood, an aggressive bacterial disease.
- May & Baker, Biovaccines Set to Open Vaccine Production Facilityon January 15, 2023 at 4:00 pm
Barring unforeseen circumstances, May & Baker Nigeria has announced that the groundbreaking ceremony for its vaccine production factory would take place in the second quarter of 2023. Managing ...
via Bing News